Dean Y. Li - 03 Jun 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
03 Jun 2024
Transactions value $
$0
Form type
4
Filing time
05 Jun 2024, 18:11:25 UTC
Previous filing
02 May 2024
Next filing
03 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +13,097 +22.2% $0.000000 72,186 03 Jun 2024 Direct F1
holding RXRX Class A Common Stock 1,422,048 03 Jun 2024 By Dean Li and Ruth Li Revocable Trust
holding RXRX Class A Common Stock 1,269,796 03 Jun 2024 By Dean Y. Li GRAT
holding RXRX Class A Common Stock 421,000 03 Jun 2024 By Dean Y. Li 2021 Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Award $0 +26,193 $0.000000 26,193 03 Jun 2024 Class A Common Stock 26,193 $8.59 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 3, 2025 or the day prior to the Issuer's 2025 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer.
F2 The shares subject to this option will vest and become exercisable on the earlier of June 3, 2025 or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.